WHO Issues First Guidelines for GLP-1 Obesity Treatments

Published 3 days ago

story

Image credit:

The Spin

Weight loss drugs targetfail symptomsto ratheraddress thanthe root causes of obesity and failrepresent toa deliverdangerous sustainableabdication resultsof beyondresponsibility, twoparticularly yearsfor children. These medications carrydon't seriousteach riskshealthier fromeating hearthabits, valvecome damagewith toserious suicideside whileeffects costinglike enormousnausea sumsand depression, yetand theypatients cannottypically compensateregain forweight theafter fundamentalstopping mismatchthem. betweenRelying modernon lifestylesexpensive pharmaceutical interventions instead of addressing diet, exercise and lifestyle changes ignores that obesity stems from normal human metabolismphysiology shapedresponding byto millenniamodern of scarcityenvironments.

The Telegraph The Pharmaceutical Journal

GLP-1 therapies represent a critical breakthrough in treating obesity as the chronic disease it is, offering proveneffective benefitstreatment forthat cardiovascularextends health,beyond diabetesweight preventionloss to reduce cardiovascular events and kidneyother functioncomplications. With 3.7over million1 obesity-relatedbillion deathspeople inaffected 2024globally and costs reaching $3 trillion annually by 2030, these medications provide an essential toolstool within comprehensive care that combinesincludes behavioral supportinterventions. Ensuring equitable access through generic production and medicalhealth treatmentsystem integration can transform obesity from an untreatable condition into a manageable chronic disease.